Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 25Carcinoma, Intraductal, Noninfiltrating 3Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Low Grade Serous Ovarian Cancer 1Locoregional Recurrence 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2 Negative Breast Cancer 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1ER+ Breast Cancer 1Anatomic Stage III Breast Cancer AJCC v8 1Anatomic Stage II Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

Letrozole 2exemestane 1dalpiciclib 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HR Positive HER2 Negative Advanced Breast Cancer × Anastrozole × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡